Dan Marks is a Venture Associate within the Venture team at RA Capital Management. Dan’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Dan holds a BS with Honors in Biology from Yale University and a PhD in Cancer Biology from the Gerstner Sloan Kettering School of Biomedical Sciences. His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells.